FDA reviewers advise no go for Novartis' serelaxin
This article was originally published in Scrip
It's never a good sign for a drug heading into an advisory committee meeting when the FDA's reviewers start off the briefing documents by advising against approval, and for Novartis, there's trouble ahead for serelaxin, a recombinant form of the human relaxin-2 hormone, which the firm is seeking to market as Reasanz.
You may also be interested in...
Novartis's latest Phase III study of serelaxin has failed, deleting a significant chunk of forecasted revenue that analysts had attributed to the heart failure drug candidate.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.